All articles by
NeuroPace’s RNS system improves quality of life in long-term treatment study
The long-term treatment study assessed 256 patients across 33 epilepsy centers with around 1,900 patient implant years of follow-up. The…
Biosense Webster begins US IDE study of Heliostar RF balloon ablation catheter
Biosense Webster has recruited and treated the first patient in the study, which is designed to assess the safety and…
Generex signs binding LoI to buy 51% stake in Regentys
Regentys is engaged in the development of treatments for patients with gastrointestinal (GI) disorders. Generex has paid an initial amount…
In2Bones launches CoLink View plating system
CoLink View Bone Plates, marketed under the CoLink View brand name, incorporate a unique combination of titanium metal and a…
Kalen Capital invests in autologous stem cell therapies developer RenovaCare
This increases his family office’s total equity investment in RenovaCare since 2013 to over $20m. “Our long-term investment in RenovaCare…
Study shows patients can determine back pain using mobile app
The study conducted by the University of Warwick has proved that digital versions of established measurements for evaluating back pain…
Clearwater, CyberMDX collaborate to support healthcare industry
The CyberMDX-Clearwater joint delivery model, being demonstrated this week at the H-ISAC Fall Summit in San Antonio, creates the most…
Pixvana, Limbix to create virtual reality therapy for adolescent depression
Pixvana, Limbix, Stony Brook, UT Austin, and Harvard researchers developed VR scenes that support Growth Mindset Training – an understanding…
Auris Health secures $220m funds to advance medical robotics platform
Auris Health has received funding under the financing round led by Partner Fund Management. New investors such as Wellington Management,…
Vectura’s VR475 asthma drug-device fails to meet primary endpoint in phase III study
VR475 is a drug device combination, which includes budesonide delivered by Vectura’s nebuliser inhalation system. The top-line results showed reduction…